E-selectin-dependent cell adhesion antagonists
AssigneeLa Jolla Cancer Research Foundation
InventorsMinoru Fukuda, Ritsuko Sawada, Shigeru Tsuboi
Life of this patent
Estimating the term…
Loading patent…
AssigneeLa Jolla Cancer Research Foundation
InventorsMinoru Fukuda, Ritsuko Sawada, Shigeru Tsuboi
Estimating the term…
The present invention provides antagonists to cell adhesion useful in controlling the negative effects of inflammation, and the metastasis of cancer cells. These antagonists are ligands to E-selectin containing the sialyl Lex structure, including sialyl Lex glycoproteins, sialyl Lex glycolipids, and sialyl Lex oligsaccharides, and other related sialyl Lex-containing molecules capable of inhibiting E-selectin mediated cell adhesion to endothelial cells. The present invention also provides antibodies against sialyl Lex determinants capable of interrupting E-selectin mediated cell adhesion, which are also considered antagonists according to the present invention. The present invention also provides methods of using the antagonists of the present invention to reduce inflammation, and methods to inhibit the process of metastasis by carcinogenic cells. The present invention-also provides nucleic acid molecules encoding the glycoprotein antagonists of the present invention, in particular soluble chimeric leukosialin, and vectors capable of expressing these nucleic acid molecules, as well as cells capable of producing sialyl Lex positive recombinant glycoproteins. The present invention further provides a method of determining metastatic potential by comparing the efficiency of E-selectin-mediated adhesion of cell samples. In addition the present invention provides a method of producing a preferred antagonist of the present invention, sialyl Lex positive glycoproteins, in particular, sialy Lex positive chimeric leukosialin.
An antagonist to E-selectin mediated cell adhesion wherein said antagonist is selected from a group of molecules consisting of a ligand to E-selectin containing sialyl Lex-termini, and an anti-sialyl Lex antibody.
A nucleic acid sequence encoding a soluble chimeric glycoprotein.
A nucleic acid sequence encoding a soluble chimeric leukosialin-IgG.
A mammalian cell containing both a vector capable of directing the expression of a soluble glycoprotein and a vector capable of directing the expression of a fucosyltransferase enzyme which directs sialyl Lex synthesis.
A mammalian cell containing both a vector capable of directing the expression of a soluble chimeric leukosialin and a vector capable of directing the expression of a fucosyltransferase enzyme which directs sialy Lex synthesis.
A method of recombinantly producing glycoproteins expressing sialyl Lex termini comprising transfecting a culture of appropriate mammalian cells with both a vector which directs the expression of a soluble glycoprotein and a vector which directs the expression of a fucosyltransferase enzyme.
A method of inhibiting E-selectin mediated adhesion of carcinoma cells to endothelial cells comprising administering a sialyl Lex-glycoprotein, a sialyl Lex-glycolipid, or a sialyl Lex-chimeric glycoprotein to a subject.
A method of determining the metastatic potential for a sample of carcinoma cells comprising determining the percentage of carcinoma cells which bind to E-selectin expressing cells.
Dependencies are inferred from the claim text.